JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 23, 2003; DOI: 10.1124/jpet.103.052316


0022-3565/03/3063-1174-1181$20.00
JPET 306:1174-1181, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.052316v1
306/3/1174    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, N.
Right arrow Articles by Bacon, K. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, N.
Right arrow Articles by Bacon, K. B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NICOTINAMIDE

INFLAMMATION AND IMMUNOPHARMACOLOGY

The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents

Noriyuki Yamamoto, Keisuke Takeshita, Michitaka Shichijo, Toshio Kokubo, Masako Sato, Kosuke Nakashima, Mina Ishimori, Hiroichi Nagai, Ying-Fu Li, Takeshi Yura, and Kevin B. Bacon

Research Center Kyoto, Bayer Yakuhin, Ltd., Kyoto, Japan (N.Y., K.T., M.S., T.K., M.S., K.N., M.I., Y.-F.L., T.Y., K.B.B.); and Department of Pharmacology, Gifu Pharmaceutical University, Gifu, Japan (H.N.)

Spleen tyrosine kinase (Syk) tyrosine kinase plays essential roles in receptors for Fc portion of immunoglobulins and B cell receptor complex signaling in various inflammatory cells; therefore, inhibitors of Syk kinase may show potential as antiasthmatic/allergic therapeutics. We identified 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606), a potent (Ki = 7.5 nM) and selective inhibitor of Syk kinase. BAY 61-3606 inhibited not only degranulation (IC50 values between 5 and 46 nM) but also lipid mediator and cytokine synthesis in mast cells. BAY 61-3606 was highly efficacious in basophils obtained from healthy human subjects (IC50 = 10 nM) and seems to be at least as potent in basophils obtained from atopic (high serum IgE) subjects (IC50 = 8.1 nM). B cell receptor activation and receptors for Fc portion of IgG signaling in eosinophils and monocytes were also potently suppressed by BAY 61-3606. Oral administration of BAY 61-3606 to rats significantly suppressed antigen-induced passive cutaneous anaphylactic reaction, bronchoconstriction, and bronchial edema at 3 mg/kg. Furthermore, BAY 61-3606 attenuated antigen-induced airway inflammation in rats. Based on these anti-inflammatory effects of BAY 61-3606 both in vitro and in vivo, it was demonstrated that Syk may play a very critical role in the pathogenesis of allergic reactions.


Received April 1, 2003; accepted May 20, 2003.

Address correspondence to: Dr. Noriyuki Yamamoto, Research Center Kyoto, Bayer Yakuhin, Ltd., 6-5-1-3, Kunimidai, Kizu-cho, Soraku-gun, Kyoto 619-0216 Japan. E-mail: noriyuki.yamamoto.ny{at}bayer.co.jp




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
W. S. Yang, J. W. Seo, N. J. Han, J. Choi, K.-U. Lee, H. Ahn, S. K. Lee, and S.-K. Park
High glucose-induced NF-{kappa}B activation occurs via tyrosine phosphorylation of I{kappa}B{alpha} in human glomerular endothelial cells: involvement of Syk tyrosine kinase
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1065 - F1075.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Luangdilok, C. Box, L. Patterson, W. Court, K. Harrington, L. Pitkin, P. Rhys-Evans, P. O-charoenrat, and S. Eccles
Syk Tyrosine Kinase Is Linked to Cell Motility and Progression in Squamous Cell Carcinomas of the Head and Neck
Cancer Res., August 15, 2007; 67(16): 7907 - 7916.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, M. Baluom, K. Qu, E. Herlaar, A. Lau, C. Young, et al.
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 998 - 1008.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. Matsubara, T. Koya, K. Takeda, A. Joetham, N. Miyahara, P. Pine, E. S. Masuda, C. H. Swasey, and E. W. Gelfand
Syk Activation in Dendritic Cells Is Essential for Airway Hyperresponsiveness and Inflammation
Am. J. Respir. Cell Mol. Biol., April 1, 2006; 34(4): 426 - 433.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Matsubara, G. Li, K. Takeda, J. E. Loader, P. Pine, E. S. Masuda, N. Miyahara, S. Miyahara, J. J. Lucas, A. Dakhama, et al.
Inhibition of Spleen Tyrosine Kinase Prevents Mast Cell Activation and Airway Hyperresponsiveness
Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 56 - 63.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Ruiz-Ballesteros, M. Mollejo, A. Rodriguez, F. I. Camacho, P. Algara, N. Martinez, M. Pollan, A. Sanchez-Aguilera, J. Menarguez, E. Campo, et al.
Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis
Blood, September 1, 2005; 106(5): 1831 - 1838.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.